TY - JOUR
T1 - Next-generation cell therapies
T2 - The emerging role of CAR-NK cells
AU - Basar, Rafet
AU - Daher, May
AU - Rezvani, Katayoun
N1 - Funding Information:
This work was supported in part by the generous philanthropic contribution to The University of Texas MD Anderson Cancer Center Moonshots Program by grants from CPRIT (RP160693), the Leukemia & Lymphoma Society (6555-18), and Stand Up to Cancer (award SU2C-AACR-DT29-19); by grants (1 R01 CA211044-01, 5 P01CA148600-03, and P50CA100632-16) from the National Institutes of Health (NIH); and by a grant (CA016672) to the MD Anderson Cancer Center from the NIH.
Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings, including practical, logistical, and toxicity issues. Given these concerns, there is a rapidly growing interest in natural killer cells as alternative vehicles for CAR engineering, given their unique biological features and their established safety profile in the allogeneic setting. Other immune effector cells, such as invariant natural killer T cells, γδ T cells, and macrophages, are attracting interest as well and eventually may be added to the repertoire of engineered cell therapies against cancer. The pace of these developments will undoubtedly benefit from multiple innovative technologies, such as the CRISPR-Cas gene editing system, which offers great potential to enhance the natural ability of immune effector cells to eliminate refractory cancers.
AB - T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings, including practical, logistical, and toxicity issues. Given these concerns, there is a rapidly growing interest in natural killer cells as alternative vehicles for CAR engineering, given their unique biological features and their established safety profile in the allogeneic setting. Other immune effector cells, such as invariant natural killer T cells, γδ T cells, and macrophages, are attracting interest as well and eventually may be added to the repertoire of engineered cell therapies against cancer. The pace of these developments will undoubtedly benefit from multiple innovative technologies, such as the CRISPR-Cas gene editing system, which offers great potential to enhance the natural ability of immune effector cells to eliminate refractory cancers.
UR - http://www.scopus.com/inward/record.url?scp=85097311163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097311163&partnerID=8YFLogxK
U2 - 10.1182/HEMATOLOGY.2020002547
DO - 10.1182/HEMATOLOGY.2020002547
M3 - Article
C2 - 33275752
AN - SCOPUS:85097311163
SN - 1520-4391
VL - 20
SP - 570
EP - 578
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -